Literature DB >> 32637648

Missing outcome data management in acute stroke trials testing iv thrombolytics. Is there risk of bias?

Jose Fernandez-Ferro1, Lee H Schwamm2, Miguel A Descalzo3, Rachael MacIsaac4, Patrick D Lyden5, Kennedy R Lees4.   

Abstract

INTRODUCTION: Missing outcome data may undermine interpretation of randomised clinical trials by weakening power and limiting apparent effect size. We assessed bias and inefficiency of two imputation methods commonly used in stroke trials evaluating the efficacy of iv thrombolysis. PATIENTS AND METHODS: We searched the virtual international stroke trials archive (VISTA)-acute for ischaemic stroke patients with 90-day modified Rankin scale as an outcome, and known thrombolysis status. We excluded any with missing 30-day modified Rankin scale. We planned two analyses; first, we calculated odds ratios for outcome in thrombolysed versus not thrombolysed from imputed-only data, (a) among patients with missing modified Rankin scale 90 and (b) among matched patients with intact data (using propensity score methods and relevant covariates). Imputation approaches were last observation carried forward (LOCF) or multiple imputation. Outcome comparisons used dichotomisation and shift analysis. Thereafter, we calculated whole-population odds ratios using LOCF and multiple imputation (also through dichotomisation and shift analysis); first with the original 1.5% missing outcome data, and then artificially increasing the burden (5%; 10%; 20%; 30%).
RESULTS: We considered 9657 patients from eight of the studies included in VISTA, 3034 (31%) thrombolysed. Missing data replacement by LOCF with analysis by dichotomisation gave the highest estimate of thrombolysis influence. Imputing while increasing the burden of missing data progressively raised the odds ratios estimates, though thresholds for overestimation were 10% for LOCF; 20% for multiple imputation.Discussion: Replacing missing outcome data tended to overestimate differences of thrombolysed versus non-thrombolysed patients, but had minimal impact below a 10% burden of missing data.
Conclusion: In the specific context of acute stroke trials testing iv thrombolytics, replacing missing data by carrying forward the last observation tended to overestimate treatment odds ratios more than multiple imputation. © European Stroke Organisation 2020.

Entities:  

Keywords:  Stroke; complete case analysis; epidemiology; last observation carried forward; missing data; multiple imputation; trials

Year:  2020        PMID: 32637648      PMCID: PMC7313360          DOI: 10.1177/2396987320905457

Source DB:  PubMed          Journal:  Eur Stroke J        ISSN: 2396-9873


  22 in total

1.  Safety and efficacy of desmoteplase given 3-9 h after ischaemic stroke in patients with occlusion or high-grade stenosis in major cerebral arteries (DIAS-3): a double-blind, randomised, placebo-controlled phase 3 trial.

Authors:  Gregory W Albers; Rüdiger von Kummer; Thomas Truelsen; Jens-Kristian S Jensen; Gabriela M Ravn; Bjørn A Grønning; Hugues Chabriat; Ku-Chou Chang; Antonio E Davalos; Gary A Ford; James Grotta; Markku Kaste; Lee H Schwamm; Ashfaq Shuaib
Journal:  Lancet Neurol       Date:  2015-04-30       Impact factor: 44.182

2.  Aspiration Thrombectomy After Intravenous Alteplase Versus Intravenous Alteplase Alone.

Authors:  J Mocco; Osama O Zaidat; Rüdiger von Kummer; Albert J Yoo; Rishi Gupta; Demetrius Lopes; Don Frei; Harish Shownkeen; Ron Budzik; Zahra A Ajani; Aaron Grossman; Dorethea Altschul; Cameron McDougall; Lindsey Blake; Brian-Fred Fitzsimmons; Dileep Yavagal; John Terry; Jeffrey Farkas; Seon Kyu Lee; Blaise Baxter; Martin Wiesmann; Michael Knauth; Donald Heck; Syed Hussain; David Chiu; Michael J Alexander; Timothy Malisch; Jawad Kirmani; Laszlo Miskolczi; Pooja Khatri
Journal:  Stroke       Date:  2016-08-02       Impact factor: 7.914

3.  Thrombectomy for Stroke at 6 to 16 Hours with Selection by Perfusion Imaging.

Authors:  Gregory W Albers; Michael P Marks; Stephanie Kemp; Soren Christensen; Jenny P Tsai; Santiago Ortega-Gutierrez; Ryan A McTaggart; Michel T Torbey; May Kim-Tenser; Thabele Leslie-Mazwi; Amrou Sarraj; Scott E Kasner; Sameer A Ansari; Sharon D Yeatts; Scott Hamilton; Michael Mlynash; Jeremy J Heit; Greg Zaharchuk; Sun Kim; Janice Carrozzella; Yuko Y Palesch; Andrew M Demchuk; Roland Bammer; Philip W Lavori; Joseph P Broderick; Maarten G Lansberg
Journal:  N Engl J Med       Date:  2018-01-24       Impact factor: 91.245

4.  A test of the missing data mechanism for repeated categorical data.

Authors:  T Park; C S Davis
Journal:  Biometrics       Date:  1993-06       Impact factor: 2.571

5.  Stent-retriever thrombectomy after intravenous t-PA vs. t-PA alone in stroke.

Authors:  Jeffrey L Saver; Mayank Goyal; Alain Bonafe; Hans-Christoph Diener; Elad I Levy; Vitor M Pereira; Gregory W Albers; Christophe Cognard; David J Cohen; Werner Hacke; Olav Jansen; Tudor G Jovin; Heinrich P Mattle; Raul G Nogueira; Adnan H Siddiqui; Dileep R Yavagal; Blaise W Baxter; Thomas G Devlin; Demetrius K Lopes; Vivek K Reddy; Richard du Mesnil de Rochemont; Oliver C Singer; Reza Jahan
Journal:  N Engl J Med       Date:  2015-04-17       Impact factor: 91.245

6.  Thrombectomy within 8 hours after symptom onset in ischemic stroke.

Authors:  Tudor G Jovin; Angel Chamorro; Erik Cobo; María A de Miquel; Carlos A Molina; Alex Rovira; Luis San Román; Joaquín Serena; Sonia Abilleira; Marc Ribó; Mònica Millán; Xabier Urra; Pere Cardona; Elena López-Cancio; Alejandro Tomasello; Carlos Castaño; Jordi Blasco; Lucía Aja; Laura Dorado; Helena Quesada; Marta Rubiera; María Hernandez-Pérez; Mayank Goyal; Andrew M Demchuk; Rüdiger von Kummer; Miquel Gallofré; Antoni Dávalos
Journal:  N Engl J Med       Date:  2015-04-17       Impact factor: 91.245

7.  Desmoteplase 3 to 9 Hours After Major Artery Occlusion Stroke: The DIAS-4 Trial (Efficacy and Safety Study of Desmoteplase to Treat Acute Ischemic Stroke).

Authors:  Rüdiger von Kummer; Etsuro Mori; Thomas Truelsen; Jens-Kristian S Jensen; Bjørn A Grønning; Jochen B Fiebach; Karl-Olof Lovblad; Salvador Pedraza; Javier M Romero; Hugues Chabriat; Ku-Chou Chang; Antoni Dávalos; Gary A Ford; James Grotta; Markku Kaste; Lee H Schwamm; Ashfaq Shuaib; Gregory W Albers
Journal:  Stroke       Date:  2016-11-01       Impact factor: 7.914

8.  Randomised double-blind placebo-controlled trial of thrombolytic therapy with intravenous alteplase in acute ischaemic stroke (ECASS II). Second European-Australasian Acute Stroke Study Investigators.

Authors:  W Hacke; M Kaste; C Fieschi; R von Kummer; A Davalos; D Meier; V Larrue; E Bluhmki; S Davis; G Donnan; D Schneider; E Diez-Tejedor; P Trouillas
Journal:  Lancet       Date:  1998-10-17       Impact factor: 79.321

9.  Shift analysis versus dichotomization of the modified Rankin scale outcome scores in the NINDS and ECASS-II trials.

Authors:  Sean I Savitz; Robert Lew; Erich Bluhmki; Werner Hacke; Marc Fisher
Journal:  Stroke       Date:  2007-11-01       Impact factor: 7.914

10.  The benefits and harms of intravenous thrombolysis with recombinant tissue plasminogen activator within 6 h of acute ischaemic stroke (the third international stroke trial [IST-3]): a randomised controlled trial.

Authors:  Peter Sandercock; Joanna M Wardlaw; Richard I Lindley; Martin Dennis; Geoff Cohen; Gordon Murray; Karen Innes; Graham Venables; Anna Czlonkowska; Adam Kobayashi; Stefano Ricci; Veronica Murray; Eivind Berge; Karsten Bruins Slot; Graeme J Hankey; Manuel Correia; Andre Peeters; Karl Matz; Phillippe Lyrer; Gord Gubitz; Stephen J Phillips; Antonio Arauz
Journal:  Lancet       Date:  2012-05-23       Impact factor: 79.321

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.